---
title: "Simcere Signs Exclusive Global Licensing Agreement With Boehringer Ingelheim for SIM0709"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/273811721.md"
datetime: "2026-01-27T08:30:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273811721.md)
  - [en](https://longbridge.com/en/news/273811721.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273811721.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/273811721.md) | [English](https://longbridge.com/en/news/273811721.md)


# Simcere Signs Exclusive Global Licensing Agreement With Boehringer Ingelheim for SIM0709

Simcere Pharmaceutical Group Ltd. announced that its subsidiary, Jiangsu Simcere Pharmaceutical Co., Ltd., has entered into an exclusive licensing agreement with Boehringer Ingelheim. Under the agreement, Boehringer Ingelheim will have the exclusive global rights, outside of Greater China, to SIM0709, a TL1A/IL-23p19 bispecific antibody developed for the treatment of inflammatory bowel disease. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260127-12002047), on January 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [SIMCERE PHARMA (02096.HK)](https://longbridge.com/zh-HK/quote/02096.HK.md)

## 相關資訊與研究

- [United Laboratories Clarifies Dividend Wording in 2025 Results Notice](https://longbridge.com/zh-HK/news/281135255.md)
- [SSY Group Wins China Approval for Upadacitinib Bulk Drug](https://longbridge.com/zh-HK/news/281103720.md)
- [Clover Biopharmaceuticals Details Capped Payment Deal With Gavi, Easing US$224 Million Exposure](https://longbridge.com/zh-HK/news/281511185.md)
- [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-HK/news/281054154.md)
- [Baiyunshan Pharma Gets Approval for Carbocisteine Oral Solution's Registration in Macau](https://longbridge.com/zh-HK/news/281478355.md)